P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results.

10.1158/0008-5472.sabcs-3126 ◽

2009 ◽

Cited By ~ 3

Author(s):

E Mayer ◽

M Kozloff ◽

R Qamar ◽

B Klencke ◽

J Balkissoon ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Safety And Efficacy ◽

Randomized Phase Ii ◽

Phase II Trial with Gemcitabine, Paclitaxel and Bevacizumab for the First Line Treatment of Metastatic Breast Cancer.

10.1158/0008-5472.sabcs-09-6089 ◽

2009 ◽

Cited By ~ 2

Author(s):

A. Guardino ◽

M. Chen ◽

M. Levy ◽

C. Chen

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Abstract P5-17-05: Sorafenib plus Ixabepilone as First-Line Treatment for Patients with HER2-Negative Metastatic Breast Cancer: Preliminary Results of the Phase II Trial of the Sarah Cannon Research Institute

10.1158/0008-5472.sabcs12-p5-17-05 ◽

2012 ◽

Author(s):

DA Yardley ◽

J Barton ◽

N Dickson ◽

D Shipley ◽

DR Drosick ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Preliminary Results ◽

First Line Treatment ◽

Research Institute

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

Annals of Oncology ◽

10.1093/annonc/mdx772 ◽

2018 ◽

Vol 29 (3) ◽

pp. 661-668 ◽

Cited By ~ 1

Author(s):

A. Gennari ◽

Z. Sun ◽

U. Hasler-Strub ◽

M. Colleoni ◽

M.J. Kennedy ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Maintenance Schedules ◽

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer

Cancer Investigation ◽

10.3109/07357907.2010.496755 ◽

2010 ◽

Vol 28 (9) ◽

pp. 925-931 ◽

Cited By ~ 14

Author(s):

Denise A. Yardley ◽

Michael McCleod ◽

Fred Schreiber ◽

Patrick Murphy ◽

Jeffrey Patton ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Activity and safety of vinorelbine and capecitabine as first-line treatment in patients with metastatic breast cancer – a phase II trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70741-9 ◽

2008 ◽

Vol 6 (7) ◽

pp. 177 ◽

Cited By ~ 4

Author(s):

R. Palumbo ◽

A. Bernardo ◽

M. Strada ◽

C. Teragni ◽

G. Poggi ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2011.03.019 ◽

2011 ◽

Vol 11 (4) ◽

pp. 211-220 ◽

Cited By ~ 23

Author(s):

Adam Brufsky ◽

Karen Hoelzer ◽

Thaddeus Beck ◽

Robert Whorf ◽

Mark Keaton ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A Phase II Trial of Split, Low-Dose Docetaxel and Low-Dose Capecitabine: A Tolerable and Efficacious Regimen in the First-Line Treatment of Patients with HER2/neu–Negative Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2008.n.017 ◽

2008 ◽

Vol 8 (2) ◽

pp. 162-167 ◽

Cited By ~ 6

Author(s):

Orlando Silva ◽

Gilberto Lopes ◽

Daniel Morgenzstern ◽

Christopher Lobo ◽

Philomena Doliny ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.1075 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 1075-1075 ◽

Cited By ~ 13

Author(s):

M. A. Danso ◽

J. L. Blum ◽

N. J. Robert ◽

L. Krekow ◽

R. Rotche ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.1032 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 1032-1032 ◽

Cited By ~ 2

Author(s):

N. W. Peacock ◽

J. R. Infante ◽

D. A. Yardley ◽

H. A. Burris ◽

F. A. Greco ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Weekly Docetaxel ◽